The low cell cycle activity of cancer cells and activated signatures of macrophages and CD8+ T cells are related to the promising effect of T-DM1 in the treatment of HER2-positive breast cancer, providing a treatment target to reverse resistance to T-DM1. Here, ERBB2 is linked to cancer.